Health
Anti-cancer drug’s mode of operation deciphered – EurekAlert
Freiburg researchers show how the membrane protein CD20 keeps the immune system’s antibody-producing cells in check.
IMAGE: Freiburg researchers investigate how the membrane protein CD20 organizes the nanostructures on the B cell membrane.
view more
Credit: Illustration: Julia Jullesova
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. A team headed by Professor Dr. Michael Reth used cell cultures, healthy cells, and cells from cancer patients…
-
Business16 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
General22 hours agoMichael Beatty, veteran current affairs journalist and animal welfare advocate, dies aged 76
-
Noosa News15 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
Noosa News12 hours agoTips to improve engagement – Proctor